Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 5. Clinical features of cytomegalovirus retinitis at diagnosis. Studies of ocular complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group.

A. Gilpin,R. Lewis,P. Clogston,V. Fainstein,R. Gross,T. Samo,C. Tuttle,D. Jabs,L. Apuzzo,J. Bartlett,L. Coleson,J. Dunn,L. Eldred,J. Feinberg,T. Flynn

DOI: https://doi.org/10.1016/S0002-9394(14)70778-0

Abstract:

What problem does this paper attempt to address?

An in-vivo investigation of the therapeutic effect of pulsed focused ultrasound on tumor growth.

C. Ma,D. Cvetkovic,Lili Chen,Xiaoming Chen

DOI: https://doi.org/10.1118/1.4901352

2014-12-01

Abstract:PURPOSE High-intensity focused ultrasound (HIFU) has been investigated for ablative therapy and drug enhancement for gene therapy and chemotherapy. The aim of this work is to explore the feasibility of pulsed focused ultrasound (pFUS) for cancer therapy using an in vivo animal model. METHODS A clinical HIFU system (InSightec ExAblate 2000) integrated with a 1.5 T GE MR scanner was used in this study. Suitable ultrasound parameters were investigated to perform nonthermal sonications, keeping the temperature elevation below 4 °C as measured in real time by MR thermometry. LNCaP cells (10(6)) were injected into the prostates of male mice (n = 20). When tumors reached a diameter of about 5 mm in 3D as measured on magnetic resonance imaging (MRI), the tumor-bearing mice (n = 8) were treated with pFUS (1 MHz frequency; 25 W acoustic power; 0.1 duty cycle; 60 s duration). A total of 4-6 sonications were used to cover the entire tumor volume under MR image guidance. The animals were allowed to survive for 4 weeks after the treatment. The tumor growth was monitored on high-resolution (0.2 mm) MRI weekly post treatment and was compared with that of the control group (n = 12). RESULTS Significant tumor growth delay was observed in the tumor-bearing mice treated with pFUS. The mean tumor volume for the pFUS treated mice remained the same 1 week after the treatment while the mean tumor volume of the control mice grew 42% over the same time. Two weeks after the pFUS treatment, the control group had a mean tumor volume 40% greater than that of the treated group. There was a greater variation in tumor volume at 4 weeks post treatment for both treated and control mice and a slightly faster tumor growth for the pFUS treated mice. CONCLUSIONS The authors' results demonstrated that pFUS may have a great potential for cancer therapy. Further experiments are warranted to understand the predominantly nonthermal cell killing mechanisms of pFUS and to derive optimal ultrasound parameters and fractionation schemes to maximize the therapeutic effect of pFUS.

Engineering,Medicine
Focused Ultrasound Treatment of a Spheroid In Vitro Tumour Model

Lisa Landgraf,Adam Kozlowski,Xinrui Zhang,Marc Fournelle,Franz-Josef Becker,Steffen Tretbar,Andreas Melzer

DOI: https://doi.org/10.3390/cells11091518

IF: 6

2022-04-30

Cells

Abstract:Focused ultrasound (FUS) is a non-invasive technique producing a variety of biological effects by either thermal or mechanical mechanisms of ultrasound interaction with the targeted tissue. FUS could bring benefits, e.g., tumour sensitisation, immune stimulation, and targeted drug delivery, but investigation of FUS effects at the cellular level is still missing. New techniques are commonly tested in vitro on two-dimensional (2D) monolayer cancer cell culture models. The 3D tumour model-spheroid-is mainly utilised to mimic solid tumours from an architectural standpoint. It is a promising method to simulate the characteristics of tumours in vitro and their various responses to therapeutic alternatives. This study aimed to evaluate the effects of FUS on human prostate and glioblastoma cancer tumour spheroids in vitro. The experimental follow-up enclosed the measurements of spheroid integrity and growth kinetics, DNA damage, and cellular metabolic activity by measuring intracellular ATP content in the spheroids. Our results showed that pulsed FUS treatment induced molecular effects in 3D tumour models. With the disruption of the spheroid integrity, we observed an increase in DNA double-strand breaks, leading to damage in the cancer cells depending on the cancer cell type.
MR-guided high-intensity focused ultrasound: current status of an emerging technology

Alessandro Napoli,Michele Anzidei,Federica Ciolina,Eugenio Marotta,Beatrice Cavallo Marincola,Giulia Brachetti,Luisa Di Mare,Gaia Cartocci,Fabrizio Boni,Vincenzo Noce,Luca Bertaccini,Carlo Catalano

DOI: https://doi.org/10.1007/s00270-013-0592-4

Abstract:The concept of ideal tumor surgery is to remove the neoplastic tissue without damaging adjacent normal structures. High-intensity focused ultrasound (HIFU) was developed in the 1940s as a viable thermal tissue ablation approach. In clinical practice, HIFU has been applied to treat a variety of solid benign and malignant lesions, including pancreas, liver, prostate, and breast carcinomas, soft tissue sarcomas, and uterine fibroids. More recently, magnetic resonance guidance has been applied for treatment monitoring during focused ultrasound procedures (magnetic resonance-guided focused ultrasound, MRgFUS). Intraoperative magnetic resonance imaging provides the best possible tumor extension and dynamic control of energy deposition using real-time magnetic resonance imaging thermometry. We introduce the fundamental principles and clinical indications of the MRgFUS technique; we also report different treatment options and personal outcomes.
MR-guided Focused Ultrasound for Musculoskeletal Applications

Christin A. Tiegs-Heiden

DOI: https://doi.org/10.1016/j.mric.2024.02.006

IF: 1.376

2024-03-25

Magnetic Resonance Imaging Clinics of North America

Abstract:• MR-guided focused ultrasound (MRgFUS) can be used for the ablation of both benign and malignant bone and soft tissue lesions. • MRgFUS is US Food and Drug Administration approved and has the CE mark for the treatment of osteoid osteoma and painful bone metastases; it also has the CE mark for the treatment of lumbar facet joints. • MRgFUS is also being evaluated for sacroiliac joint pain, knee osteoarthritis, desmoid fibromatosis, peripheral nerve ablation, and vascular malformations. MR-guided focused ultrasound (MRgFUS) can be used for the ablation of both benign and malignant bone and soft tissue lesions. MRgFUS is US Food and Drug Administration approved and has the CE mark for the treatment of osteoid osteoma and painful bone metastases; it also has the CE mark for the treatment of lumbar facet joints. MRgFUS is also being evaluated for sacroiliac joint pain, knee osteoarthritis, desmoid fibromatosis, peripheral nerve ablation, and vascular malformations.

radiology, nuclear medicine & medical imaging
A comparative analysis of low intensity ultrasound effects on living cells: from simulation to experiments

Giulia Tamboia,Michele Campanini,Veronica Vighetto,Luisa Racca,Luca Spigarelli,Giancarlo Canavese,Valentina Cauda

DOI: https://doi.org/10.1007/s10544-022-00635-x

2022-10-24

Abstract:Ultrasounds are already broadly exploited in clinical diagnostics and are now becoming a powerful and not harmful tool in antitumoral therapies, as they are able to produce damages towards cancer cells, thank to inertial cavitation and temperature increase. The use of US alone or combined to molecular compounds, microbubbles or solid-state nanoparticles is the focus of current research and clinical trials, like thermoablation, drug sonoporation or sonodynamic therapies. In the present work, we discuss on the non-thermal effects of ultrasound and the conditions which enable oxygen radical production and which role they can have in provoking the death of different cancer cell lines. In this perspective, we set a mathematical model to predict the pressure spatial distribution in a defined water sample volume and thus obtain a map of acoustic pressures and acoustic intensities of the applied ultrasound at different input powers. We then validate and verify these numerical results with direct acoustic measurements and by detecting the production of reactive oxygen species (ROS) by means of sonochemiluminescence (SCL) and electron paramagnetic resonance (EPR) spectroscopy, applied to the same water sample volume and using the same US input parameters adopted in the simulation. Finally, the various US conditions are applied to two different set of cancer cell lines, a cervical adenocarcinoma and a hematological cancer, Burkitt's lymphoma. We hypothesize how the ROS generation can influence the recorded cell death. In a second set of experiments, the role of semiconductor metal oxide nanocrystals, i.e. zinc oxide, is also evaluated by adding them to the water and biological systems. In particular, the role of ZnO in enhancing the ROS production is verified. Furthermore, the interplay among US and ZnO nanocrystals is evaluated in provoking cancer cell death at specific conditions. This study demonstrates a useful correlation between numerical simulation and experimental acoustic validation as well as with ROS measurement at both qualitative and quantitative levels during US irradiation of simple water solution. It further tries to translate the obtained results to justify one of the possible mechanisms responsible of cancer cell death. It thus aims to pave the way for the use of US in cancer therapy and a better understanding on the non-thermal effect that a specific set of US parameters can have on cancer cells cultured in vitro.
Radiofrequency ablation versus magnetic resonance guided focused ultrasound surgery for minimally invasive treatment of osteoid osteoma: a propensity score matching study

Carlo Masciocchi,Luigi Zugaro,Francesco Arrigoni,Giovanni Luca Gravina,Silvia Mariani,Alice La Marra,Carmine Zoccali,Stefano Flamini,Antonio Barile

DOI: https://doi.org/10.1007/s00330-015-4111-7

IF: 7.034

2015-11-26

European Radiology

Abstract:ObjectivesTo compare outcomes in pain relief and motor functional recovery in patients with an osteoid osteoma treated by magnetic resonance guided focused ultrasound surgery (MRgFUS) or radiofrequency ablation (RFA) using a propensity score matching study design.MethodsThirty patients with osteoid osteomas were included in this institutional review board (IRB)-approved study. MRgFUS was performed in 15 subjects. These subjects were matched by propensity analysis with a group of 15 subjects treated by RFA. Pain relief in terms of complete response (CR) and motor functional recovery were measured.ResultsA similar proportion of subjects treated by MRgFUS (94 %) or RFA (100 %) experienced CR 12 weeks after treatment, with no significant difference. The improvement in pain control following MRgFUS or RFA paralleled with improved motor functional recovery. The treatment failure rate was 6.6 % in the MRgFUS group and 0 % in the RFA group. No major complications were observed following either ablative treatment.ConclusionsAlthough this study involved a limited number of patients, MRgFUS favourably improves perceived pain and motor functional recovery, with no major complications. No difference was found in the achievement of primary and secondary outcome measures with respect to RFA.Key Points• To demonstrate the effectiveness of a recent technique for treating osteoid osteoma• MRgFUS results compared with results of the gold standard treatment (RFA)• MRgFUS is effective both from a clinical and functional point of view• No significant side effects compared with RFA

radiology, nuclear medicine & medical imaging
Ultrasound inhibits tumor growth and selectively eliminates malignant brain tumor in vivo

Nitsa Buaron,Antonella Mangraviti,Yuan Wang,Ann Liu,Mariangela Pedone,Eric Sankey,Itay Adar,Abraham Nyska,Riki Goldbart,Tamar Traitel,Henry Brem,Betty Tyler,Joseph Kost

DOI: https://doi.org/10.1002/btm2.10660

2024-04-03

Bioengineering & Translational Medicine

Abstract:Glioma is one of the most common primary malignant brain tumors. Despite progress in therapeutic approaches, the median survival of patients with glioma remains less than 2 years, generating the need for new therapeutic approaches. Ultrasound (US) is widely used in medical fields and is used as a therapeutic tool mainly for improving the performance of therapeutic entities. In this study, we examined a novel approach using low frequency US (20 kHz) (LFUS) as an independent treatment tool for malignant glioma, since primary studies showed that cancer cells are more susceptible to LFUS than healthy cells. LFUS safety and efficacy were examined in a 9L gliosarcoma‐bearing female Fischer 344 rats. Two LFUS protocols were examined: a one‐time treatment (US1X), and two treatments 24 h apart (US2X). For safety evaluation, rats were monitored for weight change and pain measurements. For efficacy, tumor volume was measured as a function of time and the tumor structural chances were examined histopathologically. LFUS treatment showed rapid inhibition of tumor growth, seen as soon as 12 h after US application. In addition, LFUS was found to affect the tumor structure, which was more extensive (>60% of tumor area) in smaller tumors. In US2X, the tumor tissue was completely destroyed, and an extensive immune response was observed. Importantly, the treatment was highly selective, keeping the healthy tissue surrounding the tumor unharmed. We developed a highly efficient and selective therapeutic protocol for treating malignant glioma with minimal side effects based solely on LFUS.

engineering, biomedical
A Novel Strategy to Improve Radiotherapy Effectiveness: First-in-Human MR-guided Focused Ultrasound-Stimulated Microbubbles (MRgFUS+MB) Radiation Enhancement Treatment

Moore-Palhares Daniel,Saifuddin Murtuza,Ho Ling,Lu Lin,Dasgupta Archya,Smoragiewicz Martin,Karam Irene,Bayley Andrew,Sahgal Arjun,Poon Ian,Czarnota Gregory J

DOI: https://doi.org/10.29328/journal.jro.1001052

2023-08-24

Journal of Radiology and Oncology

Abstract:Background and aim: Preclinical in vitro and in vivo experiments suggest that radiation-induced tumour cell death can be enhanced 10- to 40-fold when combined with focused-ultrasound (FUS)-stimulated microbubbles (MB). The acoustic exposure of MB in the tumour volume causes vasculature perturbation, activation of the acid sphingomyelinase (ASMase) ceramide pathway, and resultant endothelial cell apoptosis. When the tumour is subsequently treated with radiation, there is increased endothelial cell death and anoxic tumour killing. Here we describe a first-in-human experience treating patients with magnetic resonance (MR)-guided FUS-stimulated MB (MRgFUS+MB) radiation enhancement. Case presentation: A head and neck cancer patient with recurrent disease underwent radiotherapy for 5 separate sites of locoregional disease followed by systemic therapy. The first consisted of a course of 45 Gy in 5 fractions alone, the second of 30 Gy in 5 fractions with hyperthermia, and the three others of 20-30 Gy in 5 fractions along with MRgFUS+MB treatment. The treatment methodology used an MR-coupled FUS-device operating at 500 KHz and 540 kPa peak negative pressure with an insonification time of 750 ms spread over 5 minutes to stimulate intravenously administered MB within tumour target. All sites treated with stimulated MB had a complete radiological response, and subsequently, the patient’s other cutaneous metastatic disease disappeared. The patient has been under surveillance for over two years without active treatment or disease progression. Discussion: MRgFUS+MB was well-tolerated with no reported treatment-related adverse events, which can be attributed to the capability of FUS to selectively stimulate MB within the tumour volume while sparing the surrounding normal tissue. Sustained local control at all target sites aligns with earlier preclinical findings suggesting the radiation enhancement potential of FUS+MB. Conclusion: MRgFUS+MB represents a novel and promising therapy for enhancing radiation efficacy and improving therapeutic index with potential improvements in disease control.
Selection criteria for osteoid osteomas/osteoblastoma’s treatment by ablation with radiofrequency needles or high intensity focused ultrasound: our experience

Giulia Spano,Julia Daffinà,Antonio Izzo,Luigi Zugaro,Ernesto Di Cesare,Antonio Barile,Francesco Arrigoni

DOI: https://doi.org/10.1007/s44326-024-00018-x

2024-06-10

Abstract:Abstract Purpose Osteoid Osteomas (OO) and Osteoblastomas (OB) are relatively rare benign bone lesions necessitating effective treatment to alleviate associated pain and functional limitations. Radiofrequency Thermal Ablation (RFA) and Focused Ultrasound (MRgFUS) have emerged as minimally invasive techniques for their management. This study aims to retrospectively evaluate and compare the selection criteria for these two treatments. Methods A retrospective analysis was conducted on 102 cases of OO/OB treated between January 2013 and July 2020. Eight potential factors influencing treatment selection were assessed, including lesion characteristics and proximity to critical structures. Statistical regression using the Wilcoxon test was performed to compare treatment outcomes. Results Significant differences were observed between the RFA and MRgFUS groups concerning the proximity of vascular-nervous structures to the lesion ( p = 0.001), lesion depth ( p < 0.001), nidus size ( p < 0.001), and the presence of an acoustic window ( p < 0.001). Additionally, lesion depth ( p < 0.001), sclerosis ( p = 0.03), and nidus size ( p = 0.02) were significant factors. Conclusions Our findings underscore the importance of considering multiple factors when selecting a treatment modality for OO and OB. While both RFA and MRgFUS offer comparable efficacy, careful assessment of patient-specific features, particularly the presence of an acoustic window and sclerosis, should guide treatment decisions.
Pharmacology of reticulo-ruminal motor function.

Y. Ruckebusch

DOI: https://doi.org/10.1111/J.1365-2885.1983.TB00001.X

IF: 1.567

1983-12-01

Journal of Veterinary Pharmacology and Therapeutics

Abstract:experimental studies of the pharmacological control of the reticulo-rumen reveal two major central inhibitory pathways: (i) an adrenergic system which inhibits the magnitude of reticulo-ruminal movements and involves alpha 2-receptors and (ii) an inhibitory opioid system, which modulates the rate of the contractions. In addition, the coarseness of the stomach contents and the masticatory movements represent the major excitatory inputs to the gastric centres, hence the hypomotility and stasis observed in disease processes which lead to anorexia. Finally, the amplitude of reticular contractions will tend to vary inversely with the rate of contractions following the administration of stimulatory drugs acting centrally. As a practical statement, a direct action on the gastric centres is possible for drugs such as alpha blockers and/or morphine antagonists. Reflex excitatory effects may be induced by stimulation of muscarinic receptors of the reticulorumen wall as long as it remains below the threshold of a neuromuscular blockade. The highly complex mechanisms whereby reticuloruminal movements are regulated provide for (i) drug interactions, like those of histamine antagonists and opioid agonists, (ii) reflex inhibition of both amplitude and frequency of contractions arising from an enhanced abomaso-duodenal motility, like that induced by serotonin, and (iii) reflex stimulation of the rate of contractions elicited by the i.v. injection of catecholamines, an effect limited to the sheep. The multifactorial nature of reticuloruminal function suggests that treatment is unlikely to effect a cure but should materially re-establish a more normal motility. Further studies, required in diseased animals to provide for a curative use of drugs and a more thorough understanding of drug effects in normal ruminants, represent only a first step toward rational therapy. In addition, the extrapolation of drug effects from sheep to calves or cattle could be hazardous, especially for drugs whose mechanisms of action are currently unknown.
Magnetic Resonance-Guided Focused Ultrasound Ablation in Abdominal Moving Organs: A Feasibility Study in Selected Cases of Pancreatic and Liver Cancer

Michele Anzidei,Alessandro Napoli,Francesco Sandolo,Beatrice Cavallo Marincola,Michele Di Martino,Pasquale Berloco,Sandro Bosco,Mario Bezzi,Carlo Catalano

DOI: https://doi.org/10.1007/s00270-014-0861-x

2014-03-05

CardioVascular and Interventional Radiology

Abstract:PurposeThis study was designed to evaluate preliminarily the feasibility and safety of magnetic resonance-guided focused ultrasound (MRgFUS) for treatment of solid tumors in the upper abdomen.MethodsWe enrolled one patient with hepatocellular carcinoma and two patients with pancreatic adenocarcinoma for MRgFUS ablation. Treatments were performed on a 3T scanner under controlled respiration. Treatment response was evaluated at 1, 3, and 6 months by assessing the nonperfused volume (NPV) of ablated tissue at MR and the degree of pain severity and pain interference.ResultsIn the patient with HCC, NPV was 100 % after treatment and 85 % at 3 and 6 months follow-up. Histological analysis after liver transplantation showed fibrosis in the ablated area with minimal local tumor recurrence. In the two patients with pancreatic adenocarcinoma, NPV was 80 and 85 % after treatment and 70 and 80 % at 3 and 6 months follow-up. Pain severity and pain interference respectively decreased from a mean of 7 and 6.7 points, respectively, to a mean of 3 and 2 points after treatment.ConclusionsMRgFUS can be feasible and safe in selected patients with solid tumors in abdominal moving organs. However, this technique has several limitations due to the interposition of the rib cage or intestinal loops into the path of the ultrasonic beam, as well as to organ motion. Future technical developments are needed to implement advanced motion detection within the system to control organ and lesion position in real-time and keep the focus of the ultrasound beam on the targeted lesion.

radiology, nuclear medicine & medical imaging,cardiac & cardiovascular systems
Safety and Short-Term Efficacy of MR Guided Focused Ultrasound Surgery for Bone Metastasis-Induced Pain Palliation

Hairui Xiong,Qian Zhou,Junhai Zhang,Haoxiong Li,Ye Chen,Qiong Li,Ying Tang,Zhenwei Yao,Xiaoyuan Feng

DOI: https://doi.org/10.3760/cma.j.issn.1005-1201.2017.06.010

2017-01-01

Abstract:Objective To discuss the safety and short-term efficacy of MR-guided focused ultrasound surgery (MRgFUS) for pain palliation of bone metastases patients.Methods Fourteen patients with painful bone metastases were recruited in this prospective study.The treating efficacy was characterized by numerical rating scale (NRS),the brief pain inventory quality of life (BPI-QOL) survey,and Karnosky performance status scale (KPS).Adverse events occurred pre-and post-treatment were analyzed.Normal distributed statistics was analyzed by using paired-samples t test or Wilcoxon rank sum test.Results Fourteen patients were treated with MRgFUS,2 patients dropped out of the study.The NRS ratings are 6.50(4.00),5.00 (5.25),2.50(5.00),2.50(4.75),2.00 (6.00) for pre-treatment,one week,one month,two months,and three months,respectively.Such variances of NRS ratings were statistically significant (Z=-2.773,-2.740,-2.769,-2.675;P＜0.05).The BPI-QOL ratings were (42.42± 8.27),(30.67 ± 12.29),(29.17±15.38),(29.92± 17.67) and (35.67± 19.28),respectively.The BPI-QOL ratings decreased in the first two months after the treatment which is statistically significant (t=3.231,2.820 and 2.453;P＜0.05);whereas for the third month,the BPI-QOL rating was statistically insignificant compared with the one before the treatment (P＞0.05).The KPS ratings were 80(28),80(20),65(45) for pre-treatment,one week and three months after treatment,respectively.Three months after the treatment,the KPS ratings decreased which was statistically significant compared with the one before the treatment (Z=-2.204,P＜0.05).After the treatment,one patient developed deep venous thrombosis,three patients reported lower extremities numbness,two patients had soft tissue edema around the lesions.Conclusions MRgFUS is effective for short-term pain palliation of bone metastases.Such noninvasive technique is safe and can improve patients' living condition.
From Focused Ultrasound Tumor Ablation to Brain Blood Barrier Opening for High Grade Glioma: A Systematic Review

Luca Paun,Alessandro Moiraghi,Gianpaolo Jannelli,Aria Nouri,Francesco DiMeco,Johan Pallud,Torstein R. Meling,Shahan Momjian,Karl Schaller,Francesco Prada,Denis Migliorini

DOI: https://doi.org/10.3390/cancers13225614

2021-11-10

Cancers

Abstract:Background: Focused Ultrasound (FUS) is gaining a therapeutic role in neuro-oncology considering its novelty and non-invasiveness. Multiple pre-clinical studies show the efficacy of FUS mediated ablation and Blood-Brain Barrier (BBB) opening in high-grade glioma (HGG), but there is still poor evidence in humans, mainly aimed towards assessing FUS safety. Methods: With this systematic review our aim is, firstly, to summarize how FUS is proposed for human HGG treatment. Secondly, we focus on future perspectives and new therapeutic options. Using PRISMA 2020 guidelines, we reviewed case series and trials with description of patient characteristics, pre- and post-operative treatments and FUS outcomes. We considered nine case series (five about tumor ablation and four about BBB opening) with FUS-treated HGG patients between 1991 and 2021. Results: Sixty-eight patients were considered in total, mostly males (67.6%), with a mean age of 50.5 ± 15.3 years old. Major complication rates were found in the tumor ablation group (26.1%). FUS has been rarely applied for direct tumoral ablation in human HGG patients with controversial results, but at the best of current studies, FUS-mediated BBB opening is showing good results with very low complication rates, paving the way for a new reliable technique to improve local chemotherapy delivery and antitumoral immune response. Conclusions: FUS can become a complementary technique to surgical resection and standard radiochemotherapy in recurrent HGG. Ongoing trials could provide in the near future more data on FUS-mediated BBB opening impact on progression-free survival, overall survival and potential drug-delivery capacities.

oncology
Novel MRI-guided focussed ultrasound stimulated microbubble radiation enhancement treatment for breast cancer

Archya Dasgupta,Murtuza Saifuddin,Evan McNabb,Ling Ho,Lin Lu,Danny Vesprini,Irene Karam,Hany Soliman,Edward Chow,Sonal Gandhi,Maureen Trudeau,William Tran,Belinda Curpen,Greg Stanisz,Arjun Sahgal,Michael Kolios,Gregory J. Czarnota

DOI: https://doi.org/10.1038/s41598-023-40551-5

IF: 4.6

2023-08-23

Scientific Reports

Abstract:Preclinical studies have demonstrated focused ultrasound (FUS) stimulated microbubble (MB) rupture leads to the activation of acid sphingomyelinase-ceramide pathway in the endothelial cells. When radiotherapy (RT) is delivered concurrently with FUS-MB, apoptotic pathway leads to increased cell death resulting in potent radiosensitization. Here we report the first human trial of using magnetic resonance imaging (MRI) guided FUS-MB treatment in the treatment of breast malignancies. In the phase 1 prospective interventional study, patients with breast cancer were treated with fractionated RT (5 or 10 fractions) to the disease involving breast or chest wall. FUS-MB treatment was delivered before 1st and 5th fractions of RT (within 1 h). Eight patients with 9 tumours were treated. All 7 evaluable patients with at least 3 months follow-up treated for 8 tumours had a complete response in the treated site. The maximum acute toxicity observed was grade 2 dermatitis in 1 site, and grade 1 in 8 treated sites, at one month post RT, which recovered at 3 months. No RT-related late effect or FUS-MB related toxicity was noted. This study demonstrated safety of combined FUS-MB and RT treatment. Promising response rates suggest potential strong radiosensitization effects of the investigational modality.

multidisciplinary sciences
Focused Ultrasound Stimulation of Microbubbles in Combination With Radiotherapy for Acute Damage of Breast Cancer Xenograft Model

Deepa Sharma,Farah Hussein,Niki Law,Golnaz Farhat,Christine Tarapacki,Lakshmanan Sannachi,Anoja Giles,Gregory J. Czarnota

DOI: https://doi.org/10.1177/15330338221132925

2022-11-22

Abstract:Technology in Cancer Research &Treatment, Volume 21, Issue , January-December 2022. Objective: Several studies have focused on the use of ultrasound-stimulated microbubbles (USMB) to induce vascular damage in order to enhance tumor response to radiation. Methods: In this study, power Doppler imaging was used along with immunohistochemistry to investigate the effects of combining radiation therapy (XRT) and USMB using an ultrasound-guided focused ultrasound (FUS) therapy system in a breast cancer xenograft model. Specifically, MDA-MB-231 breast cancer xenograft tumors were induced in severe combined immuno-deficient female mice. The mice were treated with FUS alone, ultrasound and microbubbles (FUS + MB) alone, 8 Gy XRT alone, or a combined treatment consisting of ultrasound, microbubbles, and XRT (FUS + MB + XRT). Power Doppler imaging was conducted before and 24 h after treatment, at which time mice were sacrificed and tumors assessed histologically. The immunohistochemical analysis included terminal deoxynucleotidyl transferase dUTP nick end labeling, hematoxylin and eosin, cluster of differentiation-31 (CD31), Ki-67, carbonic anhydrase (CA-9), and ceramide labeling. Results: Tumors receiving treatment of FUS + MB combined with XRT demonstrated significant increase in cell death (p = 0.0006) compared to control group. Furthermore, CD31 and Power Doppler analysis revealed reduced tumor vascularization with combined treatment indicating (P < .0001) and (P = .0001), respectively compared to the control group. Additionally, lesser number of proliferating cells with enhanced tumor hypoxia, and ceramide content were also reported in group receiving a treatment of FUS + MB + XRT. Conclusion: The study results demonstrate that the combination of USMB with XRT enhances treatment outcomes.

oncology
MR Imaging–Guided Focused Ultrasound—Clinical Applications in Managing Malignant Gliomas

Huanwen Chen,Pavlos Anastasiadis,Graeme F. Woodworth

DOI: https://doi.org/10.1016/j.mric.2024.05.006

IF: 1.376

2024-06-25

Magnetic Resonance Imaging Clinics of North America

Abstract:• MR imaging–guided focused ultrasound (MRgFUS) is an emerging noninvasive technology with great promise for managing malignant gliomas. • MRgFUS can induce direct tumor cell killing by thermal ablation, histotripsy, or sonodynamic therapy. • MRgFUS can open the blood-brain barrier to facilitate the delivery of therapeutic agents into the tumor and the release of tumor antigens and genetic materials into the systemic circulation. • MRgFUS can also modulate the tumor immune microenvironment to augment MR imaging–guided focused ultrasound (MRgFUS) is an emerging noninvasive technology with great promise for managing malignant gliomas. MRgFUS can induce direct tumor cell killing by thermal ablation, histotripsy, or sonodynamic therapy. MRgFUS can open the blood-brain barrier to facilitate the delivery of therapeutic agents into the tumor and the release of tumor antigens and genetic materials into the systemic circulation. MRgFUS can also modulate the tumor immune microenvironment to augment

radiology, nuclear medicine & medical imaging
Abstract B021: A preclinical murine model investigation; Focused ultrasound ablation of osteosarcoma induces local and systemic immunomodulation

Alayna N Hay,Elliana Vickers,Ny Luong,Victor Lopez,Sheryl Coutermarsh-Ott,Eli Vlaisavljevich,Joanne Tuohy

DOI: https://doi.org/10.1158/2326-6074.tumimm24-b021

IF: 10.1

2024-10-19

Cancer Immunology Research

Abstract:Background: Osteosarcoma (OS) is the most common primary malignant bone tumor in humans primarily occurring in children and adolescents. OS is an aggressive cancer and is typically classified as "immunologically cold" with the primary tumor microenvironment (TME) characterized as an immune desert. In a similar fashion to other cancers, the lack of immune recognition allows the primary disease to progress eventually resulting in metastatic disease. Prognosis for human OS patients without metastatic disease at the time of diagnosis who undergo definitive standard of care is 70% 5-year survival rate. In efforts to improve patient prognosis, more recent research efforts have been geared towards developing therapies to generate an anti-tumor immune response. One major challenge about generating an effective and sustainable immune response with tumor directed therapies is overcoming the immunosuppressive TME. One means of overcoming this challenge is by altering the immune TME through tumor ablation modalities. The overall goal of this study was to investigate the local and systemic immune responses associated with non-thermal focused ultrasound ablation (histotripsy) to determine the potential of histotripsy to serve as a novel immunomodulating treatment modality for OS. We hypothesized that histotripsy ablation of primary OS will result in a reduction in disease burden and stimulate a local and systemic pro-inflammatory immune response. Methods: We utilized a preclinical syngeneic orthotopic OS murine model and evaluated the local and systemic immune response 3-,7-,10-14-, and 21- days post histotripsy (DPH) with immunophenotyping via flow cytometry and immunohistochemistry, and differential gene expression analysis. Tumor ablation was evaluated by ultrasound immediately post ablation and for 2-weeks post ablation via MRI. Results:Tumor ablation was evident on ultrasound and MRI, and we observed a gross reduction in tumor size post ablation. Ablation resulted in significantly greater survival time compared to untreated tumor-bearing mice. Our IHC results revealed greater CD8 and CD4 cells compared to FoxP3 cells on the periphery of histotripsy ablated tumors. Our flow cytometry results indicate that at 3 DPH there was a peak in circulating pro-inflammatory monocytes, a significantly greater population of circulating CD8 T-cells at 14 DPH compared to untreated tumor-bearing mice, and a greater DC population at 14 DPH compared to the 3-and 7- DPH evaluated timepoints. Splenic memory CD4 T cell population increased over time post treatment. Conclusion: Our exciting results are promising and suggest that histotripsy ablation did alter both the local and systemic immune responses as hypothesized. Further investigations are warranted to continue determining the full potential of histotripsy ablation to serve as a novel treatment modality that targets both the primary tumor and induces immunomodulation to potentially mitigate metastatic disease. Citation Format: Alayna N Hay, Elliana Vickers, Ny Luong, Victor Lopez, Sheryl Coutermarsh-Ott, Eli Vlaisavljevich, Joanne Tuohy. A preclinical murine model investigation; Focused ultrasound ablation of osteosarcoma induces local and systemic immunomodulation [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr B021.

oncology,immunology
A new versatile MR-guided high-intensity focused ultrasound (HIFU) device for the treatment of musculoskeletal tumors

Paolo Cabras,Pierre Auloge,Fabrice Bing,Pramod Prabhakar Rao,Stéphanie Hoarau,Erik Dumont,Alexandre Durand,Benjamin Maurin,Benoit Wach,Loïc Cuvillon,Elodie Breton,Afshin Gangi,Jonathan Vappou

DOI: https://doi.org/10.1038/s41598-022-13213-1

IF: 4.6

2022-06-09

Scientific Reports

Abstract:Magnetic Resonance (MR) Imaging-guided High Intensity focused Ultrasound (MRgHIFU) is a non-invasive, non-ionizing thermal ablation therapy that is particularly interesting for the palliative or curative treatment of musculoskeletal tumors. We introduce a new modular MRgHIFU device that allows the ultrasound transducer to be positioned precisely and interactively over the body part to be treated. A flexible, MR-compatible supporting structure allows free positioning of the transducer under MRI/optical fusion imaging guidance. The same structure can be rigidified using pneumatic depression, holding the transducer rigidly in place. Targeting accuracy was first evaluated in vitro. The average targeting error of the complete process was found to be equal to 5.4 ± 2.2 mm in terms of focus position, and 4.7° ± 2° in terms of transducer orientation. First-in-man feasibility is demonstrated on a patient suffering from important, uncontrolled pain from a bone metastasis located in the forearm. The 81 × 47 × 34 mm 3 lesion was successfully treated using five successive positions of the transducer, under real-time monitoring by MR Thermometry. Significant pain palliation was observed 3 days after the intervention. The system described and characterized in this study is a particularly interesting modular, low-cost MRgHIFU device for musculoskeletal tumor therapy.

multidisciplinary sciences
Nanosecond Pulsed Electric Field Inhibits Proliferation and Induces Apoptosis in Human Osteosarcoma

Xudong Miao,Shengyong Yin,Zhou Shao,Yi Zhang,Xinhua Chen

DOI: https://doi.org/10.1186/s13018-015-0247-z

IF: 2.6

2015-01-01

Journal of Orthopaedic Surgery and Research

Abstract:OBJECTIVE:Recent studies suggest that nanosecond pulsed electric field (nsPEF) is a novel minimal invasive and non-thermal ablation method that can induce apoptosis in different solid tumors. But the efficacy of nsPEF on bone-related tumors or bone metastasis is kept unknown. The current study investigates antitumor effect of nsPEF on osteosarcoma MG-63 cells in vitro.METHOD:MG-63 cells were treated with nsPEF with different electric field strengths (0, 10, 20, 30, 40, and 50 kV/cm) and different pulse numbers (0, 6, 12, 18, 24, and 30 pulses). The inhibitory effect of nsPEF on the growth of MG-63 cells was measured by Cell Counting Kit-8 (CCK-8) assay at different time points (0, 3, 12, 24, and 48 h post nsPEF treatment). The apoptosis was analyzed by Hoechst stain, in situ terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL), and flow cytometric analysis. The expression of osteoprotegerin (OPG), receptor activator of NF-κB ligand (RANKL), and tumor necrosis factor α (TNF-α) was examined by reverse-transcription polymerase chain reaction (RT-PCR) and western blot.RESULTS:The CCK-8 assay showed that nsPEF induced a distinct electric field strength- and pulse number-dependent reduction of cell proliferation. For treatment parameter optimizing, the condition 40 kV/cm and 30 pulses at 24 h post nsPEF achieved the most significant apoptotic induction rate. Hoechst, TUNEL, and flow cytometric analysis showed that the cell apoptosis was induced and cells were arrested in the G0/G1 phase. PCR and western blot analysis demonstrated that nsPEF up-regulated OPG expression had no effect on RANKL, increased OPG/RANKL ratio.CONCLUSION:NsPEF inhibits osteosarcoma growth, induces apoptosis, and affects bone metabolism by up-regulating OPG, indicating nsPEF-induced apoptosis in osteosarcoma MG-63 cells. NsPEF has potential to treat osteosarcoma or bone metastasis. When nsPEF is applied on metastatic bone tumors, it might be beneficial by inducing osteoblastic differentiation without cancer proliferation. In the future, nsPEF might be one of the treatments of metastatic bone tumor.
A study combining microbubble-mediated focused ultrasound and radiation therapy in the healthy rat brain and a F98 glioma model

Stecia-Marie P. Fletcher,Amanda Chisholm,Michael Lavelle,Romy Guthier,Yongzhi Zhang,Chanikarn Power,Ross Berbeco,Nathan McDannold

DOI: https://doi.org/10.1038/s41598-024-55442-6

IF: 4.6

2024-02-29

Scientific Reports

Abstract:Focused Ultrasound (FUS) has been shown to sensitize tumors outside the brain to Radiotherapy (RT) through increased ceramide-mediated apoptosis. This study investigated the effects of FUS + RT in healthy rodent brains and F98 gliomas. Tumors, or striata in healthy rats, were targeted with microbubble-mediated, pulsed FUS (220 kHz, 102–444 kPa), followed by RT (4, 8, 15 Gy). FUS + RT (8, 15 Gy) resulted in ablative lesions, not observed with FUS or RT only, in healthy tissue. Lesions were visible using Magnetic Resonance Imaging (MRI) within 72 h and persisted until 21 days post-treatment, indicating potential applications in ablative neurosurgery. In F98 tumors, at 8 and 15 Gy, where RT only had significant effects, FUS + RT offered limited improvements. At 4 Gy, where RT had limited effects compared with untreated controls, FUS + RT reduced tumor volumes observed on MRI by 45–57%. However, survival benefits were minimal (controls: 27 days, RT: 27 days, FUS + RT: 28 days). Histological analyses of tumors 72 h after FUS + RT (4 Gy) showed 93% and 396% increases in apoptosis, and 320% and 336% increases in vessel-associated ceramide, compared to FUS and RT only. Preliminary evidence shows that FUS + RT may improve treatment of glioma, but additional studies are required to optimize effect size.

multidisciplinary sciences

Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 5. Clinical features of cytomegalovirus retinitis at diagnosis. Studies of ocular complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group.

An in-vivo investigation of the therapeutic effect of pulsed focused ultrasound on tumor growth.

Focused Ultrasound Treatment of a Spheroid In Vitro Tumour Model

MR-guided high-intensity focused ultrasound: current status of an emerging technology

MR-guided Focused Ultrasound for Musculoskeletal Applications

A comparative analysis of low intensity ultrasound effects on living cells: from simulation to experiments

Radiofrequency ablation versus magnetic resonance guided focused ultrasound surgery for minimally invasive treatment of osteoid osteoma: a propensity score matching study

Ultrasound inhibits tumor growth and selectively eliminates malignant brain tumor in vivo

A Novel Strategy to Improve Radiotherapy Effectiveness: First-in-Human MR-guided Focused Ultrasound-Stimulated Microbubbles (MRgFUS+MB) Radiation Enhancement Treatment

Selection criteria for osteoid osteomas/osteoblastoma’s treatment by ablation with radiofrequency needles or high intensity focused ultrasound: our experience

Pharmacology of reticulo-ruminal motor function.

Magnetic Resonance-Guided Focused Ultrasound Ablation in Abdominal Moving Organs: A Feasibility Study in Selected Cases of Pancreatic and Liver Cancer

Safety and Short-Term Efficacy of MR Guided Focused Ultrasound Surgery for Bone Metastasis-Induced Pain Palliation

From Focused Ultrasound Tumor Ablation to Brain Blood Barrier Opening for High Grade Glioma: A Systematic Review

Novel MRI-guided focussed ultrasound stimulated microbubble radiation enhancement treatment for breast cancer

Focused Ultrasound Stimulation of Microbubbles in Combination With Radiotherapy for Acute Damage of Breast Cancer Xenograft Model

MR Imaging–Guided Focused Ultrasound—Clinical Applications in Managing Malignant Gliomas

Abstract B021: A preclinical murine model investigation; Focused ultrasound ablation of osteosarcoma induces local and systemic immunomodulation

A new versatile MR-guided high-intensity focused ultrasound (HIFU) device for the treatment of musculoskeletal tumors

Nanosecond Pulsed Electric Field Inhibits Proliferation and Induces Apoptosis in Human Osteosarcoma

A study combining microbubble-mediated focused ultrasound and radiation therapy in the healthy rat brain and a F98 glioma model